EDU 13 - At the Cutting Edge: The Increasing Role of Salvage Radiotherapy in Relapsed/Refractory Lymphomas

Moderator(s)

• 

  Sarah Milgrom, MD

  University of Colorado Denver
  Aurora, CO

Recently, there have been exciting advances in the treatment of relapsed/refractory (R/R) lymphomas. Historically, the standard-of-care included salvage chemotherapy followed by autologous stem cell transplantation (ASCT). Today, many other salvage options are available. Radiation therapy (RT) can be a useful adjunct to improve the efficacy and/or limit the toxicity of salvage strategies. For example, appropriately selected patients with relapsed Hodgkin lymphoma experience outstanding disease control with novel systemic therapies combined with RT. This combined modality approach allows patients to avoid the toxicities associated with ASCT. Second, in patients with R/R diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment. The incorporation of RT with CAR-T cell therapy may improve patient outcomes. Lastly, RT alone can result in outstanding disease control in patients with a partial metabolic response to upfront chemotherapy. With the appropriate use of RT, these patients may avoid intensive systemic salvage therapies.

Presentations:

• 4:45 PM – 4:47 PM ET

  Introductions
  

  Speaker: Sarah Milgrom, MD – University of Colorado Denver
• 4:47 PM – 5:07 PM ET

  Radiotherapy in Combination with Novel Systemic Agents for Transplant-Free Salvage of Relapsed Hodgkin Lymphoma
  

  Speaker: Bradford Hoppe, MD, FASTRO, MPH – Mayo Clinic Florida
• 5:07 PM – 5:27 PM ET

  Radiotherapys Effective Incorporation with Chimeric Antigen Receptor (CAR)-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  

  Speaker: Timothy Robinson, MD, PhD – Yale Therapeutic Radiology
• 5:27 PM – 5:47 PM ET

  Excellent Outcomes with Radiotherapy Alone after a Partial Metabolic Response of Lymphomas to Frontline Systemic Therapy
  

  Speaker: Andrea Ng, MD, FASTRO, MPH – Dana-Farber/Brigham and Women's Cancer Center
• 5:47 PM – 6:00 PM ET

  Questions and Answers
  

  Speaker: Sarah Milgrom, MD – University of Colorado Denver